# Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/fremanezumab-versus-placebo-for-migraine-prevention-in-patients-with-documented/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michel D. Ferrari,Hans‐Christoph Diener,Xiaoping Ning,Maja Galić,Joshua M. Cohen,Ronghua Yang,Matthias Müeller,Andrew H. Ahn,Yael Carmeli Schwartz,Melissa Grozinski‐Wolff,Lindsay Janka,Messoud Ashina |
| Citations | 438 |
| DOI | 10.1016/s0140-6736(19)31946-4 |
| Fields | Medicine,Neuroscience |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2968435022 |
| PMID | 31427046 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Joshua M. Cohen](https://scholariq.org/researchers/joshua-m-cohen/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)

## Paper topics

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)
- [Vestibular and auditory disorders](https://scholariq.org/topics/vestibular-and-auditory-disorders/)
- [Traumatic Brain Injury and Neurovascular Disturbances](https://scholariq.org/topics/traumatic-brain-injury-and-neurovascular-disturbances/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.